BrainStorm Announces NurOwn(R) Expanded Access Program

NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria NEW YORK, Dec. 14, 2020 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASD... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news